In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a Phase 3 clinical study titled ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...

Bengaluru: Neurologists in Bengaluru are now seeing at least two to five cases of multiple sclerosis (MS) each month at ...

Nearly 80% of U.S. neurologists prescribing drugs for multiple sclerosis (MS) have received at least one pharma industry payment, with higher-volume prescribers more likely to be beneficiaries, finds ...

Most US neurologists treating patients with multiple sclerosis receive industry payments, with higher payments linked to higher prescribing of that company’s drugs, new research shows.

The Emirates Drug Establishment participated in the 3rd Meeting of Heads of National Drug Regulatory Authorities of the Organization of Islamic Cooperation (OIC), underscoring its role in advancing ...

CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic to Participate in Investor and Scientific Conferences in SeptemberNEW YORK, September 4, 2025 – Immunic, Inc.